Dementia With Lewy Bodies Incidence Rises Sharply After Age 65

Quantifying the Epidemiological Burden of Dementia with Lewy Bodies

Dementia with Lewy bodies is frequently cited as a leading cause of neurodegenerative decline in older adults, yet its clinical identification remains a significant challenge for frontline physicians [1, 2]. While consensus diagnostic criteria have been refined to improve homogeneity in clinical settings, the transition of these standards into routine practice is often hampered by the overlap of symptoms with Alzheimer disease and other parkinsonian syndromes [3, 4]. Misdiagnosis or delayed diagnosis carries heavy consequences, as patients with this subtype often experience higher morbidity and specific sensitivities to certain medications, such as severe neuroleptic sensitivity, compared to those with other forms of cognitive impairment [4, 5]. Furthermore, the historical lack of standardized global data has made it difficult for healthcare systems to allocate resources for specialized care and diagnostic support [6]. A comprehensive new meta-analysis now provides a clearer picture of the global epidemiological landscape and the extent of current diagnostic gaps.

Systematic Review of Global Population Data

To quantify the global burden of dementia with Lewy bodies, researchers conducted a systematic review and meta-analysis of population-based studies. The investigators sought to determine both the incidence (the rate of newly diagnosed cases over a specific period) and the prevalence (the total number of existing cases in a population at a given time). The authors searched PubMed, Embase, and Scopus from database inception through October 22, 2024. From an initial pool of 2520 screened records, the researchers identified 16 population-based studies that met rigorous inclusion criteria, with 12 studies contributing data to the final meta-analyses. To maintain clinical relevance, the researchers only included cases identified through validated diagnostic frameworks. These included consensus criteria for dementia with Lewy bodies, the Diagnostic and Statistical Manual of Mental Disorders (the standard psychiatric classification system), and the International Classification of Diseases. By utilizing these established clinical benchmarks and pooling the data using a random-effects meta-analysis (a statistical technique that accounts for variability between different study populations), the investigators aimed to provide physicians with a reliable reference for the actual burden of the disease in the general population, rather than relying on data from specialized memory clinics that may be subject to referral bias.

Age-Dependent Escalation in Disease Frequency

The meta-analysis demonstrates that the incidence and prevalence of clinically diagnosed dementia with Lewy bodies rose steeply with age, marking a profound shift in disease frequency as patients cross the 65-year threshold. In the younger cohort, defined as individuals younger than 65 years, the condition remains exceptionally rare. For this group, the researchers calculated a pooled incidence of 0.34 per 100,000 person-years (95% CI, 0.14 to 0.83) and a pooled prevalence of 2.52 per 100,000 population (95% CI, 1.43 to 4.44). These low figures in younger patients underscore the diagnostic challenge for clinicians, as early-onset symptoms of dementia with Lewy bodies may be easily misattributed to primary psychiatric disorders or other neurological conditions when they occur before the seventh decade of life. The epidemiological landscape changes dramatically for patients 65 years or older, where the disease burden increases by several orders of magnitude. Within this older population, the pooled incidence reached 46.85 per 100,000 person-years (95% CI, 23.78 to 92.30). The total disease burden in this age group was also substantial, with a pooled prevalence of 352.26 per 100,000 population (95% CI, 112.25 to 1099.79). This sharp escalation highlights the necessity for physicians to maintain a high index of clinical suspicion for Lewy body pathology in geriatric patients presenting with cognitive decline, particularly because these figures likely represent a conservative estimate due to known diagnostic insensitivity in primary care settings.

Sex Disparities and Global Variability

The meta-analysis identified a distinct sex-based disparity in the frequency of new diagnoses, suggesting that biological sex may influence disease risk or clinical presentation. The incidence was higher in males, recorded at 5.45 per 100,000 person-years (95% CI, 4.13 to 7.19), compared to 4.32 per 100,000 person-years in females (95% CI, 2.48 to 7.52). For the practicing physician, this sex difference may inform risk stratification during cognitive assessments, although the underlying mechanisms for this male predominance remain a subject of ongoing investigation. When evaluating the population as a whole, the researchers found that the pooled crude incidence across all ages was 4.79 per 100,000 person-years (95% CI, 3.90 to 5.88). Data regarding the total number of existing cases across all age groups remained sparse in the literature, as only one study reported an all-age prevalence of 19.13 per 100,000 population (95% CI, 15.38 to 23.51). Clinicians should interpret these pooled estimates with an understanding of the significant variability between the included studies. The researchers noted that between-study heterogeneity was high, characterized by an I2 value of 85% or greater. This statistical measure quantifies the proportion of variation in effect estimates that is due to real differences between study populations rather than random sampling error. Such high variability indicates that reported rates fluctuated widely across different geographic and clinical settings, suggesting that local factors, including diagnostic rigor and population demographics, heavily influence reported disease frequency.

Clinical Implications of Diagnostic Insensitivity

The researchers concluded that clinically diagnosed dementia with Lewy bodies appears uncommon in population-based studies, a finding that likely reflects chronic underdiagnosis and diagnostic insensitivity rather than true biological rarity. This discrepancy between low reported epidemiological rates and the expected clinical burden suggests that many patients remain undiagnosed or misclassified during the early stages of cognitive decline. For the practicing clinician, these findings emphasize the necessity of improved diagnostic vigilance, particularly when evaluating older adults who present with the core clinical features of fluctuating cognition, recurrent visual hallucinations, or spontaneous parkinsonism. By establishing these epidemiological benchmarks, the study provides a robust reference for future public health planning and highlights the critical need for standardized diagnostic approaches to ensure patients receive appropriate management and prognostic counseling. Beyond immediate clinical challenges, the high degree of variability in the data underscores the importance of identifying and including underrepresented populations in future research. The authors noted that current global burden estimates are limited by a lack of diverse data, which may obscure the true prevalence of the disease across different ethnic and socioeconomic groups. As the global population ages, refining these epidemiological models and enhancing diagnostic accuracy in routine practice will be paramount in mitigating the long-term impact of the disease on patients and healthcare systems.

References

1. Jones SV, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychological Medicine. 2013. doi:10.1017/s0033291713000494

2. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies.. Age and ageing. 2005. doi:10.1093/ageing/afi190

3. Ikeda M, Mori E, Iseki E, et al. Adequacy of Using Consensus Guidelines for Diagnosis of Dementia with Lewy Bodies in Clinical Trials for Drug Development.. Dementia and geriatric cognitive disorders. 2016. doi:10.1159/000441443

4. Jones SAV, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies.. Psychological medicine. 2014. doi:10.1017/S0033291713000494

5. Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [¹²³I]I-FP-CIT SPECT in routine practice.. European journal of nuclear medicine and molecular imaging. 2023. doi:10.1007/s00259-023-06171-x

6. Quartilho F, Silva JB, Cunha D, et al. IPOS-Dem Scale in the Assessment of Patients with Dementia in Palliative Care—Potential for Adaptation: A Systematic Review. 2025. doi:10.3390/jdad2040047